Predictive biomarkers of pathologic response to preoperative chemoradiotherapy in locally advanced rectal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter R. Jankovic
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors R. Jankovic1, S. Stojanovic-Rundic1, M. Micev2, Z. Krivokapic3, V. Nikolić1, I. Popov1, D. Gavrilovic1, V. Plesinac-Karapandzic1, A. Djuric-Stefanovic4, S. Radulovic1
  • 1Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, /
  • 2Institute for Gastrointestinal Diseases, Clinical Center Serbia, Belgrade, Serbia, /
  • 3Department of Surgery, Institute for Gastrointestinal Diseases, Clinical Center Serbia, Belgrade, Serbia, /
  • 4Unite of Digestive Radiology, Center of Radiology and MR, Clinical Center Serbia, Belgrade, Serbia, /

Abstract

Preoperative chemoradiotherapy (CRT) is the standard treatment option in locally advanced rectal cancer (LARC). The tumor response is estimated trough tumor and nodal down staging and the tumor regression grade. Currently, there is no method to predict a tumor response to CRT, and finding the accurate one would have a great clinical utility. Both p53 and p21 proteins belong to the cell cycle-regulating family of proteins and the loss of their activity seems to be one of the most important regulatory mechanisms of carcinogenesis in colorectal cancer. EGFR and VEGF expressions are also known to be correlated with disease outcome in patients with LARC. We aimed to evaluate whether p21, p53, VEGF and EGFR expressions could be the reliable predictors of pathological response to preoperative CRT.